ProCE Banner Activity

BTK Inhibitors in Relapsed/Refractory CLL

Slideset Download
Downloadable slides with expert analysis of the optimal use of BTK inhibitors in patients with relapsed/refractory CLL.

Released: June 10, 2020

Expiration: June 09, 2021

Share

Faculty

Nicole Lamanna

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Faculty Disclosure

Primary Author

Nicole Lamanna, MD

Associate Professor
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York